Please join MIT BioTech Group in a discussion with Cheri Ackerman, PhD and Floris Engelhardt, PhD on the challenges of translating academic science into breakthrough therapeutics and the transition from academia to early-stage entrepreneurship – as well as concrete actions the biotech community can take to rectify the historical under-representation of women in leadership teams at venture-backed companies. Dr. Ackerman is CEO at Concerto Biosciences, by way of the Broad Institute of Harvard & MIT, UC Berkeley, and Calvin University. Dr. Engelhardt is emerging CEO at Kano Therapeutics, by way of MIT, the Technical University of Munich, and Friedrich-Schiller University.
Location: iHQ 4th floor Student Venture Studio